BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Lipitor
,
rs2476601
,
MDM2
,
Response to oxidative stress
,
Leukemia
,
Heart
,
Autoimmunity
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
mlh1 protein, human
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
No studies found
Explore Curated Studies Results
Literature
Most Relevant Literature
The two-in-one hit model of the short-cut carcinogenesis of colorectal carcinomas in MLH1-associated…
Characteristics and clinical analysis of MLH1 c.463dupC gene mutation in a Lynch syndrome family].
Both MLH1 deficiency and BRAFV600E mutation are a unique characteristic of colorectal medullary carc…
MLH1 rs1800734 Pathogenic Variant among Patients with Colorectal Cancer in the Lower Northeastern Re…
Classification of MLH1 Missense VUS Using Protein Structure-Based Deep Learning-Ramachandran Plot-Mo…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer
Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Ca…
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Canc…
Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients
A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ